Cited by 11,215Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Open access

Connolly, Stuart J., Ezekowitz, Michael D., Yusuf, Salim, Eikelboom, John, Oldgren, Jonas, Parekh, Amit, Pogue, Janice, Reilly, Paul A., Themeles, Ellison, Varrone, Jeanne, Wang, Susan, Alings, Marco, Xavier, Denis, Zhu, Jun, Diaz, Rafael, Lewis, Basil S., Darius, Harald, Diener, Hans-Christoph, Joyner, Campbell D., Wallentin, Lars·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0905561

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. METHODS: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism. RESULTS: Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority). The rate of major bleeding was 3.36% per year in the warfarin group, as compared with 2.71% per year in the group receiving 110 mg of dabigatran (P=0.003) and 3.11% per year in the group receiving 150 mg of dabigatran (P=0.31). The rate of hemorrhagic stroke was 0.38% per year in the warfarin group, as compared with 0.12% per year with 110 mg of dabigatran (P<0.001) and 0.10% per year with 150 mg of dabigatran (P<0.001). The mortality rate was 4.13% per year in the warfarin group, as compared with 3.75% per year with 110 mg of dabigatran (P=0.13) and 3.64% per year with 150 mg of dabigatran (P=0.051). CONCLUSIONS: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa0905561

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,636
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. L., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.009 · Cited by 1,161
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,110
Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation
Hylek, E. M., Evans‐Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,063
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
Connolly, S. J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M. G., Healey, J. S., & Yusuf, S. (2008) · Circulation · doi:10.1161/circulationaha.107.750000 · Cited by 870

Flagged first, then by citations

Show all 18 references

Sorted by citations

Items 501–600 of 1,022

Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant
Ganetsky, M., Babu, K. M., Salhanick, S. D., Brown, R. S., & Boyer, E. W. (2011) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0178-y · Cited by 156
Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration
Borne, R. T., O’Donnell, C. I., Turakhia, M. P., Varosy, P. D., Jackevicius, C. A., Marzec, L., Masoudi, F. A., Hess, P. L., Maddox, T. M., & Ho, P. M. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0671-6 · Cited by 162
Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording
Aronsson, M., Svennberg, E., Rosenqvist, M., Engdahl, J., Al-Khalili, F., Friberg, L., Frykman-Kull, V., & Levin, L.-Å. (2015) · Europace · doi:10.1093/europace/euv083 · Cited by 154
Percutaneous Left Atrial Appendage Closure
Saw, J., & Lempereur, M. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.05.026 · Cited by 157
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
Ansell, J., & Mantha, S. H. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-02-0093 · Cited by 154
Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation
Hachamovitch, R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.121 · Cited by 155
Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes
Grisanti, L. A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01669 · Cited by 160
“The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial comparing warfarin and high dose dibagatran was composed of about 23% diabetic patients (Connolly et al., 2009).”
Background
Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision Making
Franklin, J. M., Glynn, R. J., Martin, D., & Schneeweiß, S. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1351 · Cited by 157
“In addition, a comparison of dabigatran and warfarin that was designed to match the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial replicated the effects sizes observed in the RCT.(19,62) All of these studies used newuser, active- comparator cohort designs with extensive covariate adjustment…”
ResultInfluential
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 170
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Reilly, P. A., Bernstein, R. A., Dubiel, R., Eikelboom, J. W., Glund, S., Huisman, M. V., Hylek, E. M., Kam, C. W., Kamphuisen, P. W., Kreuzer, J., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0192 · Cited by 154
Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ntaios, G., Papavasileiou, V., Diener, H.-C., Makaritsis, K., & Michel, P. (2012) · Stroke · doi:10.1161/strokeaha.112.673558 · Cited by 152
High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin
Hijazi, Z., Wallentin, L. C., Siegbahn, A., Andersson, U., Alexander, J. H., Atar, D., Gersh, B. J., Hanna, M., Harjola, V., Horowitz, J. D., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.093 · Cited by 153
Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement
Seeger, J., Gonska, B., Rodewald, C., Rottbauer, W., & Wöhrle, J. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.10.023 · Cited by 154
Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
Pan, K., Singer, D. E., Ovbiagele, B., Wu, Y., Ahmed, M., & Lee, M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005835 · Cited by 155
2018 Korean Guideline of Atrial Fibrillation Management
Joung, B., Lee, J., Lee, K. H., Kim, T., Choi, E., Lim, W., Kang, K., Uhm, J., Lim, H. E., Park, J., et al. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0339 · Cited by 157
Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
Tamayo, S. G., Peacock, W. F., Patel, M. R., Sicignano, N., Hopf, K. P., Fields, L. E., Sarich, T. C., Wu, S., Yannicelli, D., & Yuan, Ž. (2015) · Clinical Cardiology · doi:10.1002/clc.22373 · Cited by 152
National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
Dlott, J. S., George, R., Huang, X., Odeh, M. A., Kaufman, H. W., Ansell, J., & Hylek, E. M. (2014) · Circulation · doi:10.1161/circulationaha.113.002601 · Cited by 154
Risk factors for intracerebral hemorrhage differ according to hemorrhage location
Martini, S. R., Flaherty, M. L., Brown, W. M., Haverbusch, M. A., Comeau, M. E., Sauerbeck, L. R., D, B. M. K. M., Deka, R., Kleindorfer, D., Moomaw, C. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318276896f · Cited by 152
Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
Fox, K. A. A., Lucas, J. E., Pieper, K. S., Bassand, J., Camm, A. J., Fitzmaurice, D. A., Goldhaber, S. Z., Goto, S., Haas, S. K., Hacke, W., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017157 · Cited by 161
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Clarkesmith, D., Pattison, H. M., Khaing, P., & Lane, D. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008600.pub3 · Cited by 152
Stroke prevention in atrial fibrillation—An Asian stroke perspective
Tse, H., Wang, Y. J., Ai-Abdullah, M. A., Borromeo, A., Chiang, C., Krittayaphong, R., Singh, B. B., Vora, A. M., Wang, C., Zubaid, M., et al. (2013) · Heart Rhythm · doi:10.1016/j.hrthm.2013.03.017 · Cited by 150
Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
Coyle, D., Coyle, K., Cameron, C. G., Lee, K. S., Kelly, S., Steiner, S., & Wells, G. A. (2013) · Value in Health · doi:10.1016/j.jval.2013.01.009 · Cited by 154
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri‐procedural/bleeding management
Tran, H., Joseph, J. E., Young, L., McRae, S. J., Curnow, J. L., Nandurkar, H. H., Wood, P., & McLintock, C. (2014) · Internal Medicine Journal · doi:10.1111/imj.12448 · Cited by 152
Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin
Zalesak, M., Siu, K., Francis, K. M., Chen, Y. X., Alvrtsyan, H., Rao, Y., Walker, D. R., Sander, S. D., Miyasato, G., Matchar, D. B., et al. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000192 · Cited by 151
Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure
Wong, J. A., Conen, D., Gelder, I. C. V., McIntyre, W. F., Crijns, H. J. G. M., Wang, J., Gold, M. R., Hohnloser, S. H., Lau, C., Capucci, A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.519 · Cited by 152
Reversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 150
Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
Chan, Y., See, L., Tu, H., Yeh, Y., Chang, S., Wu, L., Lee, H., Wang, C., Kuo, C., & Kuo, C.-T. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008150 · Cited by 155
“Dabigatran with 110 mg twice daily was the only low-dose NOAC that was independently compared with warfarin among the 3 pivotal NOAC studies.(2) The Asian subgroup analysis from the RE-LY trial (Randomized Table 3.”
Method
Drug and dietary interactions of the new and emerging oral anticoagulants
Walenga, J. M., & Adıgüzel, C. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02286.x · Cited by 152
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study
Chang, H., Zhou, M., Tang, W., Alexander, G. C., & Singh, S. (2015) · BMJ · doi:10.1136/bmj.h1585 · Cited by 150
Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients
Lamberts, M., Stærk, L., Olesen, J. B., Fosbøl, E. L., Hansen, M. L., Harboe, L., Lefèvre, C., Evans, D., & Gislason, G. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004517 · Cited by 154
Atrial Fibrillation
Michaud, G. F., & Stevenson, W. G. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2023658 · Cited by 156
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
Huisman, M. V., Lip, G. Y. H., Diener, H., Dubner, S., Halperin, J. L., Chang, S., Rothman, K. J., Teutsch, C., Zint, K., Ackermann, D., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.12.006 · Cited by 148
Adverse Drug Events as a Cause of Hospitalization in Older Adults
Salvi, F., Marchetti, A., D’Angelo, F., Boemi, M., Lattanzio, F., & Cherubini, A. (2012) · Drug Safety · doi:10.1007/bf03319101 · Cited by 153
Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation
Schneeweiß, S., Gagne, J. J., Patrick, A. R., Choudhry, N. K., & Avorn, J. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.965988 · Cited by 146
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
Diener, H., Aisenberg, J., Ansell, J., Atar, D., BREITHARDT, G. E., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Halperin, J. L., Hohnloser, S. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv643 · Cited by 147
National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999–2013
Freeman, J. V., Wang, Y., Akar, J. G., Desai, N. R., & Krumholz, H. M. (2017) · Circulation · doi:10.1161/circulationaha.116.022388 · Cited by 148
The Global Burden of Atrial Fibrillation and Stroke
Bai, Y., Wang, Y., Shantsila, A., & Lip, G. Y. H. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.03.048 · Cited by 150
Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies
Salmasi, S., Loewen, P. S., Tandun, R., Andrade, J. G., & Vera, M. A. D. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034778 · Cited by 166
Targeting factor Xa and thrombin: impact on coagulation and beyond
Esmon, C. T. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0730 · Cited by 149
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
Goto, S., Ogawa, H., Takeuchi, M., Flather, M. D., Bhatt, D. L., & on behalf of the J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq320 · Cited by 146
Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study
Staerk, L., Lip, G. Y. H., Olesen, J. B., Fosbøl, E. L., Pallisgaard, J. L., Bonde, A. N., Gundlund, A., Lindhardt, T. B., Hansen, M. L., Torp-Pedersen, C., et al. (2015) · BMJ · doi:10.1136/bmj.h5876 · Cited by 146
Site-Level Variation in and Practices Associated With Dabigatran Adherence
Shore, S., Ho, P. M., Lambert‐Kerzner, A., Glorioso, T. J., Carey, E., Cunningham, F., Longo, L., Jackevicius, C. A., Rose, A. J., & Turakhia, M. P. (2015) · JAMA · doi:10.1001/jama.2015.2761 · Cited by 145
Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF
Piccini, J. P., Fraulo, E. S., Ansell, J., Fonarow, G. C., Gersh, B. J., Go, A. S., Hylek, E. M., Kowey, P. R., Mahaffey, K. W., Thomas, L. E., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.001 · Cited by 147
Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis
Wang, Y., Fang, C., Gao, H., Bilodeau, M. L., Zhang, Z., Croce, K., Liu, S., Morooka, T., Sakuma, M., Nakajima, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70966 · Cited by 146
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
Zirlik, A., & Bode, C. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1446-0 · Cited by 158
Perioperative Management of Dabigatran
Schulman, S., Carrier, M., Lee, A. Y. Y., Shivakumar, S., Blostein, M. D., Spencer, F. A., Solymoss, S., Barty, R., Wang, G., Heddle, N. M., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015688 · Cited by 146
Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation
Graham, D. J., Baro, E., Zhang, R., Liao, J., Wernecke, M., Reichman, M. E., Hu, M., Illoh, O. A., Wei, Y., Goulding, M. R., et al. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.12.023 · Cited by 150
“prevention.(1-4) Each of the NOACs also reduced risk of intracranial hemorrhage.”
BackgroundResultInfluential
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation
Kim, J. S., She, F., Jongnarangsin, K., Chugh, A., Latchamsetty, R., Ghanbari, H., Crawford, T. C., Suwanagool, A., Sinno, M., Carrigan, T., et al. (2012) · Heart Rhythm · doi:10.1016/j.hrthm.2012.12.011 · Cited by 145
PAR-1 contributes to the innate immune response during viral infection
Antoniak, S., Owens, A. P., Baunacke, M., Williams, J., Lee, R. D., Weithäuser, A., Sheridan, P. A., Malz, R., Luyendyk, J. P., Esserman, D. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66125 · Cited by 145
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Washam, J. B., Stevens, S. R., Lokhnygina, Y. V., Halperin, J. L., BREITHARDT, G. E., Singer, D. E., Mahaffey, K. W., Hankey, G. J., Berkowitz, S. D., Nessel, C. C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61836-5 · Cited by 146
Risk of post‐thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study
Chitsike, R. S., Rodger, M. A., Kovacs, M. J., Betancourt, M. T., Wells, P. S., Anderson, D. R., Chagnon, I., Gal, G. L., Solymoss, S., Crowther, M. A., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04872.x · Cited by 146
The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?
Eikelboom, J. W., & Karthikeyan, G. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0757 · Cited by 145
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism
Fang, M. C. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6101 · Cited by 144
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation
Aulin, J., Siegbahn, A. G., Hijazi, Z., Ezekowitz, M. D., Andersson, U., Connolly, S. J., Huber, K., Reilly, P. A., Wallentin, L. C., & Oldgren, J. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.09.018 · Cited by 144
Select Drug-Drug Interactions With Direct Oral Anticoagulants
Wiggins, B. S., Dixon, D. L., Neyens, R. R., Page, R. L., II, & Gluckman, T. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.068 · Cited by 144
Management of Diabetes in Pregnancy
Ballas, J., Moore, T. R., & Ramos, G. A. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0249-0 · Cited by 146
Safety and efficacy of well managed warfarin
Sjögren, V., Grzymala-Lubanski, B., Renlund, H., Friberg, L., Lip, G. Y. H., Svensson, P. J., & Själander, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0859 · Cited by 145
Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry
Beyer-Westendorf, J., Förster, K., Ebertz, F., Gelbricht, V., Schreier, T., Gobelt, M., Michalski, F., Endig, H., Şahin, K., Tittl, L., et al. (2015) · EP Europace · doi:10.1093/europace/euu319 · Cited by 145
Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease
Lau, Y. C., Proietti, M., Guiducci, E., Blann, A. D., & Lip, G. Y. H. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.057 · Cited by 145
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation
Eikelboom, J. W., Quinlan, D. J., Hirsh, J., Connolly, S. J., & Weitz, J. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0364 · Cited by 145
Novel biomarkers of cardiovascular disease: Applications in clinical practice
Lyngbakken, M. N., Myhre, P. L., Røsjø, H. R., & Omland, T. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1525335 · Cited by 155
“Using data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial [353], the STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY (STABILITY) trial [292] and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) [354] t…”
Method
Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)
Lane, D. A., Aguinaga, L., Blomström-Lundqvist, C., Boriani, G., Dan, G.-A., Hills, M. T., Hylek, E. M., LaHaye, S. A., Lip, G. Y. H., Lobban, T., et al. (2015) · Europace · doi:10.1093/europace/euv233 · Cited by 142
Inadequate weight gain in overweight and obese pregnant women: what is the effect on fetal growth?
Catalano, P. M., Mele, L., Landon, M. B., Ramin, S. M., Reddy, U. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.02.004 · Cited by 180
Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III.
Whitlock, R. P., Healey, J. S., Vincent, J., Brady, K., Teoh, K., Royse, A. G., Shah, P. J., Guo, Y., Alings, M., Folkeringa, R., et al. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2225-319x.2013.12.06 · Cited by 144
Drug Treatment of Acute Ischemic Stroke
Bansal, S., Sangha, K. S., & Khatri, P. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0007-6 · Cited by 149
Management of Atrial Fibrillation in Patients With Structural Heart Disease
Darby, A. E., & Dimarco, J. (2012) · Circulation · doi:10.1161/circulationaha.111.019935 · Cited by 141
Antithrombotic Therapy in the Elderly
Capodanno, D., & Angiolillo, D. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.063 · Cited by 142
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial
Caterina, R. D., Renda, G., Carnicelli, A., Nordio, F., Trevisan, M., Mercuri, M. F., Ruff, C. T., Antman, E. M., Braunwald, E., & Giugliano, R. P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.031 · Cited by 149
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
de Weerdt, I., Koopmans, S. M., Kater, A. P., & van Gelder, M. (2017) · Haematologica · doi:10.3324/haematol.2017.164103 · Cited by 146
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference
Kirchhof, P., Breithardt, G., Aliot, E., Al Khatib, S., Apostolakis, S., Auricchio, A., Bailleul, C., Bax, J., Benninger, G., Blomstrom-Lundqvist, C., et al. (2013) · Europace · doi:10.1093/europace/eut232 · Cited by 141
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
Barra, M. E., Fanikos, J. R., Connors, J. M., Sylvester, K. W., Piazza, G., & Goldhaber, S. Z. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.05.041 · Cited by 141
Review of epidemiology and management of atrial fibrillation in developing countries
Nguyen, T. N., Hilmer, S. N., & Cumming, R. G. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.184 · Cited by 139
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials
Friedman, R. J., Dahl, O. E., Rosencher, N., Caprini, J. A., Kurth, A. A., Francis, C. W., Clemens, A., Hantel, S., Schnee, J. M., & Eriksson, B. I. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.021 · Cited by 141
Direct Oral Anticoagulants: A Quick Guide
Julia, S., & Uprichard, J. (2017) · European Cardiology Review · doi:10.15420/ecr.2017:11:2 · Cited by 150
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
Diener, H., Aisenberg, J., Ansell, J., Atar, D., BREITHARDT, G. E., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Halperin, J. L., Hohnloser, S. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw069 · Cited by 142
Pathophysiology of atrial fibrillation and chronic kidney disease
Ding, W. Y., Gupta, D., Wong, C. F., & Lip, G. Y. H. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa258 · Cited by 144
Gastrointestinal complications after ischemic stroke
Camara-Lemarroy, C. R., Ibarra-Yruegas, B. E., & Góngora‐Rivera, F. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.08.027 · Cited by 139
Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable
Connolly, S. J., Eikelboom, J. W., Ng, J., Hirsh, J., Yusuf, S., Pogue, J., de Caterina, R., Hohnloser, S., & Hart, R. G. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-9-201111010-00004 · Cited by 140
Stroke Prevention and Treatment
Marsh, J. D., & Keyrouz, S. G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.072 · Cited by 147
Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation
Ebertz, F., Förster, K., Gelbricht, V., Michalski, F., Köhler, C. U., Werth, S., Endig, H., Pannach, S., Tittl, L., Şahin, K., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0954 · Cited by 139
Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation
Tieleman, R. G., Plantinga, Y., Rinkes, D., Bartels, G. L., Posma, J. L., Cator, R., Hofman, C., & Houben, R. P. (2014) · Europace · doi:10.1093/europace/euu057 · Cited by 138
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
Kimachi, M., Furukawa, T. A., Kimachi, K., Goto, Y., Fukuma, S., & Fukuhara, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011373.pub2 · Cited by 144
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants
Dias, J. D., Norem, K., Doorneweerd, D. D., Thurer, R. L., Popovsky, M. A., & Omert, L. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0170-oa · Cited by 138
Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT)
Hogan, D. F., Fox, P. R., Jacob, K. A., Keene, B. W., Laste, N. J., Rosenthal, S., Sederquist, K. A., & Weng, H. (2015) · Journal of Veterinary Cardiology · doi:10.1016/j.jvc.2015.10.004 · Cited by 157
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation
Chiang, C., Wu, T.-J., Ueng, K.-C., Chao, T., Chang, K., Wang, C.-C., Lin, Y., Yin, W., Kuo, J., Lin, W., et al. (2016) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.10.005 · Cited by 138
Cognitive dysfunction in atrial fibrillation
Madhavan, M., Graff‐Radford, J., Piccini, J. P., & Gersh, B. J. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0075-z · Cited by 146
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48
Berg, D. D., Ruff, C. T., Jarolı́m, P., Giugliano, R. P., Nordio, F., Lanz, H., Mercuri, M. F., Antman, E. M., D, E. B. M., & Morrow, D. A. (2019) · Circulation · doi:10.1161/circulationaha.118.038312 · Cited by 138
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
Lip, G. Y. H., Collet, J., Caterina, R. D., Fauchier, L., Lane, D. A., Larsen, T. B., Marín, F. R., Morais, J., Narasimhan, C., Olshansky, B., et al. (2017) · EP Europace · doi:10.1093/europace/eux240 · Cited by 141
Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation
Freeman, J. V., Higgins, A. Y., Wang, Y., Du, C., Friedman, D. J., Daimee, U. A., Minges, K. E., Pereira, L., Goldsweig, A. M., Price, M. J., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.047 · Cited by 140
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
Kushnir, M., Choi, Y. Y., Eisenberg, R. E., Rao, D., Tolu, S. S., Gao, J. Y., Mowrey, W. B., & Billett, H. H. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30086-9 · Cited by 138
Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation
Tiwari, P., Colborn, K. L., Smith, D. E., Xing, F., Ghosh, D., & Rosenberg, M. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.19396 · Cited by 138
Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation
Ogawa, S., Shinohara, Y., & Kanmuri, K. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1183 · Cited by 136
Risk of Gastrointestinal Bleeding in Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis
Miller, C., Dorreen, A. P., Martel, M., Huynh, T. T., & Barkun, A. N. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.031 · Cited by 139
“Büller et al,(35) 2012 Rivaroxaban (20) Warfarin 263 d 4833 NR Büller et al,(31) 2013 Edoxaban (30-60) j Warfarin 250 d 8292 7/639 (1.”
BackgroundInfluential
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study
Paciaroni, M., Agnelli, G., Falocci, N., Tsivgoulis, G. K., Vadikolias, K., Liantinioti, C., Chondrogianni, M. E., Bovi, P., Carletti, M., Cappellari, M., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007034 · Cited by 136
Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
Pinto, D. J. P., Smallheer, J. M., Cheney, D. L., Knabb, R. M., & Wexler, R. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100146h · Cited by 138
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
Verheugt, F. W. A., & Granger, C. B. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60245-8 · Cited by 137
Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know
Conway, S. E., Hwang, A. Y., Ponte, C. D., & Gums, J. G. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1884 · Cited by 143
2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack
Wang, Y., Liu, M., & Pu, C. (2017) · International Journal of Stroke · doi:10.1177/1747493017694391 · Cited by 134
Atualização da Diretriz Brasileira de Insuficiência Cardíaca Crônica - 2012
Bocchi, E., Marcondes‐Braga, F. G., Bacal, F., Ferraz, A., Albuquerque, D., & Rodrigues, D. (2012) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2012001000001 · Cited by 142
Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Arboix, A., & Alió, J. (2012) · Current Cardiology Reviews · doi:10.2174/157340312801215791 · Cited by 133

Authors: Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H.-C., Joyner, C. D., & Wallentin, L.
Affiliations: Population Health Research Institute (CA)
Lankenau Institute for Medical Research (US)
Uppsala University (SE)
Boehringer Ingelheim (United States) (US)
Werkgroep Cardiologische centra Nederland (NL)
St. John's National Academy of Health Sciences (IN)
Fu Wai Hospital (CN)
Carmel Medical Center (IL)
Vivantes Klinikum (DE)
Sunnybrook Health Science Centre (CA)
ORCID: Connolly, Stuart J.
Ezekowitz, Michael D.
Yusuf, Salim
Eikelboom, John
Oldgren, Jonas
Parekh, Amit
Alings, Marco
Xavier, Denis
Zhu, Jun
Lewis, Basil S.
Wallentin, Lars
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-09-17
Volume: 361
Issue: 12
Pages: 1139-1151
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0905561
OpenAlex: W2136489990
Cited by: 11,215
References: 18
Citations by year: 2026: 219 · 2025: 318 · 2024: 395 · 2023: 489 · 2022: 507 · 2021: 662 · 2020: 745 · 2019: 669 · 2018: 775 · 2017: 799 · 2016: 864 · 2015: 923 · 2014: 874 · 2013: 1000 · 2012: 915
FWCI: 419.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
Figshare (submittedVersion)
UnissResearch (Università degli Studi di Sassari) (submittedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Sanofi
Daiichi-Sankyo
Eisai
Servier
Cilag
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: dabigatran, warfarin, atrial fibrillation, direct thrombin inhibitors, oral anticoagulants, stroke prevention, systemic embolism, major bleeding, hemorrhagic stroke, non-inferiority, mortality, fixed-dose dosing, bleeding risk stratification, anticoagulation
MeSH terms: Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Double-Blind Method, Dyspepsia, Embolism, Female, Follow-Up Studies, Hemorrhage, Humans, Liver, Male, Middle Aged, Myocardial Infarction, Prodrugs, Pyridines, Warfarin, Chi-Square Distribution, Proportional Hazards Models, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks